<SEC-DOCUMENT>0001654954-22-003071.txt : 20220314
<SEC-HEADER>0001654954-22-003071.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20220314101125
ACCESSION NUMBER:		0001654954-22-003071
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220314
FILED AS OF DATE:		20220314
DATE AS OF CHANGE:		20220314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASTRAZENECA PLC
		CENTRAL INDEX KEY:			0000901832
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11960
		FILM NUMBER:		22735391

	BUSINESS ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA
		BUSINESS PHONE:		011 44 20 7304 5000

	MAIL ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZENECA GROUP PLC
		DATE OF NAME CHANGE:	19930422
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a5906e.htm
<DESCRIPTION>UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2022 Issuer Direct Corporation -->
<title>a5906e</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 6-K</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Washington,
D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Report
of Foreign Issuer</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to Rule 13a-16 or 15d-16 of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">the
Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
month of March 2022</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Commission
File Number: 001-11960</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1
Francis Crick Avenue</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
Biomedical Campus</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
CB2 0AA</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">United
Kingdom</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form
20-F X Form 40-F __</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Yes __
No X</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If
&#x201C;Yes&#x201D; is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">INDEX
TO EXHIBITS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; display: table;">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Update on US review
of Fasenra in nasal polyps</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
14 March 2022 07:00 GMT</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<font style="color: #000000">Update on US regulatory review
of&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
in chronic rhinosinusitis with nasal polyps</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The US Food and Drug Administration (FDA) has issued a complete
response letter (CRL) regarding the supplemental Biologics License
Application (sBLA) for&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;(benralizumab) for&#xA0;patients with
inadequately controlled chronic rhinosinusitis with nasal polyps
(CRSwNP).</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The sBLA submitted to the FDA by AstraZeneca included data from the
OSTRO Phase III trial, which met both co-primary endpoints with a
safety profile consistent with the known profile of the
medicine.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font><font style="color: #000000">&#xA0;The
CRL requested additional clinical data and the Company is working
closely with the FDA regarding next steps. The Company remains
committed to bringing&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;to patients with CRSwNP and a second Phase
III trial,&#xA0;</font><font style="text-decoration: underline; color: #0000FF">ORCHID</font><font style="color: #000000">,
in this indication is ongoing.</font><font style="font-size: 70%; vertical-align: top; color: #000000">2</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Fasenra</font><font style="color: #000000">&#xA0;is currently
approved as an add-on maintenance treatment for severe eosinophilic
asthma in the US, EU, Japan and other countries and is approved for
self-administration in the US, EU and other
countries.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The FDA granted&#xA0;Orphan Drug Designation
(ODD)&#xA0;for&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;for eosinophilic granulomatosis with
polyangiitis in 2018, and hypereosinophilic syndrome and
eosinophilic esophagitis (EoE) in 2019.&#xA0;In November 2021, the
FDA also granted&#xA0;</font><font style="text-decoration: underline; color: #0000FF">ODD</font><font style="color: #000000">&#xA0;for&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;for&#xA0;eosinophilic gastroenteritis
(EGE)&#xA0;and&#xA0;eosinophilic gastritis (EG),&#xA0;and
a&#xA0;</font><font style="text-decoration: underline; color: #0000FF">Fast Track
Designation</font><font style="color: #000000">&#xA0;for the
treatment of&#xA0;EG&#xA0;with or without&#xA0;EGE in the
US.&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Notes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CRSwNP</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
CRSwNP&#xA0;is characterised by persistent inflammation of the
mucous membrane lining the nasal passages and sinuses accompanied
by benign growths, called nasal polyps.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3,4</font><font style="color: #000000">&#xA0;Nasal
polyps can block nasal passages and lead to breathing problems,
reduction in the sense of smell, nasal discharge, sleep disturbance
and other adverse effects on quality of life.</font><font style="font-size: 70%; vertical-align: top; color: #000000">5-7</font><font style="color: #000000">&#xA0;Eosinophilic
infiltration of the tissues is thought to play a role in the
disease pathophysiology.</font><font style="font-size: 70%; vertical-align: top; color: #000000">4,5</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Current treatments for nasal polyps include intranasal
corticosteroids (INCS) or oral corticosteroids and surgery to
remove polyps, but these often provide only short-term relief and
the need for repeated interventions can be high.</font><font style="font-size: 70%; vertical-align: top; color: #000000">8,9</font><font style="color: #000000">&#xA0;Since
2019, other biologic medicines have been approved or recommended to
treat nasal polyps.</font><font style="font-size: 70%; vertical-align: top; color: #000000">6,10-12</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
OSTRO</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
OSTRO was a randomised, double-blinded, multi-centre,
parallel-group, 56-week Phase III trial to evaluate the efficacy
and safety of&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;compared to placebo in patients with nasal
polyposis.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;was
evaluated in patients, regardless of blood eosinophil count with or
without asthma, who were symptomatic despite standard of care
therapy, including current use of INCS for at least four weeks
prior to enrolment and a history of systemic corticosteroid use
and/or surgery for nasal polyps.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font><font style="color: #000000">&#xA0;Patients
were randomised to receive either&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;30mg or placebo subcutaneously every four
weeks for the first three doses and every eight weeks
thereafter.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The primary outcome measures of the trial were: the effect
of&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;on nasal polyp burden, assessed by change
from baseline in endoscopic total nasal polyp score, at week 40
compared to placebo; the effect of&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;on patient-reported nasal blockage, assessed
by change from baseline in mean nasal blockage score (NBS), at week
40 compared to placebo.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font><font style="color: #000000">&#xA0;OSTRO
involved 413 patients in Europe and North
America.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
OSTRO is part of AstraZeneca's clinical trial programme
for&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;in CRSwNP which also includes the ongoing
Phase III ORCHID trial, among others.</font><font style="font-size: 70%; vertical-align: top; color: #000000">2</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ORCHID</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
ORCHID is a randomised, double-blinded, multi-centre,
parallel-group, 56-week Phase III trial to evaluate the efficacy
and safety of&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;compared to placebo in patients with
eosinophilic CRSwNP.</font><font style="font-size: 70%; vertical-align: top; color: #000000">2</font><font style="color: #000000">&#xA0;The
primary outcome measures of the trial are: the effect
of&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;on nasal polyp burden, assessed by change
from baseline in endoscopic total nasal polyp score, at week 56
compared to placebo; the effect of&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">&#xA0;on patient-reported nasal blockage, assessed
by change from baseline in mean NBS, at week 56 compared to
placebo.</font><font style="font-size: 70%; vertical-align: top; color: #000000">2</font><font style="color: #000000">&#xA0;The
trial is expected to read out in the second half of
2023.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Fasenra</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Fasenra</font><font style="color: #000000">&#xA0;(benralizumab) is
a monoclonal antibody that binds directly to IL-5 receptor alpha on
eosinophils and attracts natural killer cells to induce rapid and
near-complete depletion of blood and tissue eosinophils in most
patients via apoptosis (programmed cell death).</font><font style="font-size: 70%; vertical-align: top; color: #000000">13,14</font><font style="color: #000000">&#xA0;Nasal
polyps are a strong indicator of the eosinophilic phenotype in
severe asthma and response to&#xA0;</font><font style="font-style: italic; color: #000000">Fasenra</font><font style="color: #000000">, including reductions in exacerbation and
improvement in lung function.</font><font style="font-size: 70%; vertical-align: top; color: #000000">15-17</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Fasenra</font><font style="color: #000000">&#xA0;is currently
approved as an add-on maintenance treatment for severe eosinophilic
asthma in the US, EU, Japan and other countries, and is approved
for self-administration in the US, EU and other
countries.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Fasenra</font><font style="color: #000000">&#xA0;is in development
for other eosinophilic diseases including atopic dermatitis,
bullous pemphigoid, chronic obstructive pulmonary disease, chronic
spontaneous urticaria, EoE, EG/EGE, EGPA, HES and non-cystic
fibrosis bronchiectasis.</font><font style="font-size: 70%; vertical-align: top; color: #000000">18-26</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Fasenra</font><font style="color: #000000">&#xA0;was developed by
AstraZeneca and is in-licensed from BioWa, Inc., a wholly owned
subsidiary of Kyowa Kirin Co., Ltd., Japan.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca in Respiratory &amp; Immunology</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Respiratory &amp; Immunology, part of BioPharmaceuticals, is one of
AstraZeneca's main disease areas and is a key growth driver for the
Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca is an established leader in respiratory care with a
50-year heritage. The Company aims to transform the treatment of
asthma and COPD by focusing on earlier biology-led treatment,
eliminating preventable asthma attacks, and removing COPD as a
top-three leading cause of death. The Company's early respiratory
research is focused on emerging science involving immune
mechanisms, lung damage and abnormal cell-repair processes in
disease and neuronal dysfunction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
With common pathways and underlying disease drivers across
respiratory and immunology, AstraZeneca is following the science
from chronic lung diseases to immunology-driven disease areas. The
Company's growing presence in immunology is focused on five mid- to
late-stage franchises with multi-disease potential, in areas
including rheumatology (including systemic lupus erythematosus),
dermatology, gastroenterology, and systemic eosinophilic-driven
diseases. AstraZeneca's ambition in Respiratory &amp; Immunology is
to achieve disease modification and durable remission for millions
of patients worldwide.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal &amp; Metabolism, and Respiratory &amp;
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit&#xA0;</font><font style="text-decoration: underline; color: #0000FF">astrazeneca.com</font><font style="color: #000000">&#xA0;and
follow the Company on Twitter&#xA0;</font><font style="text-decoration: underline; color: #0000FF">@AstraZeneca</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Contacts</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
For details on how to contact the Investor Relations Team, please
click&#xA0;</font><font style="text-decoration: underline; color: #0000FF">here</font><font style="color: #000000">.
For Media contacts, click&#xA0;</font><font style="text-decoration: underline; color: #0000FF">here</font><font style="color: #000000">.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-family: Times New Roman; font-size: 13px">
References</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">1.&#xA0;&#xA0; Bachert
C,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al</font><font style="color: #000000; font-size: 13px">. Efficacy
and safety of benralizumab in chronic rhinosinusitis with nasal
polyps: A randomized, placebo-controlled
trial.&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">J Allergy
Clin Immunol</font><font style="color: #000000; font-size: 13px">.
2021; [IN PRESS]. DOI:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://doi.org/10.1016/j.jaci.2021.08.030</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">2.&#xA0;&#xA0;
Clinicaltrials.gov. Efficacy and Safety Study of Benralizumab in
Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
(ORCHID). Available at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/ct2/show/NCT04157335</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">3.&#xA0;&#xA0; Bachert C,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. Phenotypes and Emerging Endotypes of Chronic
Rhinosinusitis.&#xA0;</font><font style="font-style: italic; color: #000000">J Allergy Clin Immunol
Pract.</font><font style="color: #000000">&#xA0;2016; 4 (4):
621-628.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">4.&#xA0;&#xA0; Newton JR,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. A review of nasal
polyposis.&#xA0;</font><font style="font-style: italic; color: #000000">Ther Clin Risk
Manag.</font><font style="color: #000000">&#xA0;2008; 4 (2):
507-512.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">5.&#xA0;&#xA0; Hopkins C. Chronic Rhinosinusitis
with Nasal Polyps.&#xA0;</font><font style="font-style: italic; color: #000000">N Engl J
Med.</font><font style="color: #000000">&#xA0;2019; 381 (1):
55-63.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">6.&#xA0;&#xA0; Stevens
WW,&#xA0;</font><font style="font-style: italic; color: #000000">et
al</font><font style="color: #000000">. Chronic Rhinosinusitis with
Nasal Polyps.&#xA0;</font><font style="font-style: italic; color: #000000">J Allergy Clin Immunol
Pract</font><font style="color: #000000">. 2016; 4 (4):
565-572.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">7.&#xA0;&#xA0; Abdalla S,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. Prevalence of sinonasal outcome test (SNOT-22)
symptoms in patients undergoing surgery for chronic rhinosinusitis
in the England and Wales National prospective
audit.&#xA0;</font><font style="font-style: italic; color: #000000">Clin</font><font style="color: #000000">&#xA0;Otolaryngol. 2012; 37 (4):
276-282.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">8.&#xA0;&#xA0; Ren L,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. Biologics for the treatment of chronic
rhinosinusitis with nasal polyps - state of the
art.&#xA0;</font><font style="font-style: italic; color: #000000">World Allergy Organ
J</font><font style="color: #000000">.
2019;12(8):100050.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">9.&#xA0;&#xA0; DeConde
AS,&#xA0;</font><font style="font-style: italic; color: #000000">et
al</font><font style="color: #000000">. Prevalence of polyp
recurrence after endoscopic sinus surgery for chronic
rhinosinusitis with nasal polyposis.&#xA0;</font><font style="font-style: italic; color: #000000">The
Laryngoscope</font><font style="color: #000000">. 2017; 127 (3):
550-555.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">10.&#xA0;
Xolair (omalizumab) US prescribing information; 2021.</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">11.&#xA0;
Dupixent (dupilumab) US prescribing information; 2021.</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12.&#xA0;
Nucala (mepolizumab) US prescribing information; 2022.</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">13.&#xA0; Kolbeck R,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. MEDI-563, a humanized anti-IL-5 receptor a mAb
with enhanced antibody-dependent cell-mediated cytotoxicity
function.&#xA0;</font><font style="font-style: italic; color: #000000">J Allergy Clin
Immunol</font><font style="color: #000000">. 2010; 125:
1344-1353.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">14.&#xA0; Pham T,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. Reductions in eosinophil biomarkers by
benralizumab in patients with asthma.&#xA0;</font><font style="font-style: italic; color: #000000">Respir Med</font><font style="color: #000000">. 2016; 111: 21-29.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">15.&#xA0; Bleecker ER,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. Efficacy and safety of benralizumab for patients
with severe asthma uncontrolled with high-dosage inhaled
corticosteroids and long-acting b2-agonists (SIROCCO): a
randomised, multicentre, placebo-controlled phase 3
trial.&#xA0;</font><font style="font-style: italic; color: #000000">Lancet</font><font style="color: #000000">. 2016;388:2115-2127.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">16.&#xA0; FitzGerald JM,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. Benralizumab, an anti-interleukin-5 receptor
alpha monoclonal antibody, as add-on treatment for patients with
severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised,
double-blind, placebo-controlled phase 3
trial.&#xA0;</font><font style="font-style: italic; color: #000000">Lancet</font><font style="color: #000000">. 2016;388:2128-2141.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">17.&#xA0; Canonica S,&#xA0;</font><font style="font-style: italic; color: #000000">et al</font><font style="color: #000000">. Benralizumab improves symptoms of patients with
severe, eosinophilic asthma with a diagnosis of nasal
polyposis.&#xA0;</font><font style="font-style: italic; color: #000000">Allergy</font><font style="color: #000000">. 2022;77:150-161.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">18.&#xA0; Clinicaltrials.gov.
Efficacy and Safety Study of the Use of Benralizumab for Patients
With Moderate to Severe Atopic Dermatitis. Available
at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.clinicaltrials.gov/ct2/show/NCT04605094</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">19.&#xA0; ClinicalTrials.gov. A
Study to Investigate the Use of Benralizumab in Patients With
Bullous Pemphigoid. (FJORD). Available at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/ct2/show/NCT04612790</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">20.&#xA0; Clinicaltrials.gov.
Efficacy and Safety of Benralizumab in Moderate to Very Severe
Chronic Obstructive Pulmonary Disease (COPD) With a History of
Frequent Exacerbations (RESOLUTE). Available
at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/ct2/show/NCT04053634</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">21.&#xA0; Clinicaltrials.gov. A
Study to Investigate the Use of Benralizumab in Patients With
Moderate to Severe Chronic Spontaneous Urticaria. (ARROYO).
Available at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.clinicaltrials.gov/ct2/show/NCT04612725</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">22.&#xA0; Clinicaltrials.gov. A
Study of Benralizumab in Patients With Eosinophilic Esophagitis
(MESSINA). Available at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/ct2/show/NCT04543409</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">23.&#xA0;
AstraZeneca Data on File (HUDSON trial).</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">24.&#xA0; Clinicaltrials.gov. A
Study to Evaluate if Benralizumab Compared to Mepolizumab May be
Beneficial in the Treatment of Eosinophilic Granulomatosis With
Polyangiitis (EGPA) (MANDARA). Available
at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/ct2/show/NCT04157348</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">25.&#xA0; Clinicaltrials.gov. A
Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab
in Patients With Hypereosinophilic Syndrome (HES) (NATRON).
Available at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/ct2/show/NCT04191304</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">26.&#xA0; EU Clinical Trials
Register. A Multicentre, Randomised, Double-blind, Parallel-group,
Placebo-controlled, 52-Week, Phase III Study With an Open-label
Extension to Evaluate the Efficacy and Safety of Benralizumab in
Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE). EudraCT
number: 2020-004068-24. Available at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.clinicaltrialsregister.eu/ctr-search/search?query=MAHALE</font><font style="color: #000000; font-size: 13px">.
[Last accessed: February 2022].</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Adrian Kemp</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Company Secretary</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">AstraZeneca
PLC</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
14 March 2022</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By: /s/
Adrian Kemp</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Name:
Adrian Kemp</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Title:
Company Secretary</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
